

Shoppers Stop Ltd (SS)

Other income saves the day

Revenue at Rs. 10,463 mn - up by 13.3% yoy & down 15.4% qoq
 EBITDA at Rs. 1,667 mn - up by 7.7% yoy & down 23.4% qoq
 EBITDA margin at 15.9% - down 80 bps yoy & down 170 bps qoq
 Adj PAT at Rs. 238 mn – up 66.3% yoy & down 35.6% qoq

Performance above expectation:

- Private brands growth was -8% yoy at Rs 1450mn and they were at 12% of sales.
- Intune : Sale of Rs 160 mn in Q4FY24; YTD sales of Rs 360 mn. Intune mature stores are EBITDA positive. Conversion of SS clients to Intune clients is 33%.
- Beauty (excluding beauty distribution) grew by 7% yoy to Rs 2180 mn. Besuty distribution was Rs 340mn. Total beauty was at 18% of sales. Makeovers were 2,20,000.
- Beauty distribution sales were at Rs 420mn, YTD it is Rs 1,190mn. The business is EBITDA positive.
- Average Transaction Value (ATV), the amount spent by consumers per billing, was up 8% yoy to Rs 4,581, down 9.33% qoq. Average selling price (ASP) was Rs 1,677, up 6% yoy.
- 7 Department, 12 INTUNE and 3 Beauty stores were added in the quarter.
- Added 5 new cities to take the total to 62.
- Investments in new stores was Rs 80mn, Quest mall launch was Rs 50mn and inventory write off was Rs 90mn.

Future Outlook

- SS is aggressively expanding – SS plans to open about 100 stores (including 60 Intune and 15 department stores) and renovate a few stores.
- SS does not plan to borrow beyond the working capital line of credit of Rs 1500mn and Rs 3500mn line of term loans with banks.

Key Risks

- SS' beauty business continues to see slow growth due to competition. Beauty is a stated growth driver for SS.
- SS' private brands continues to see slow growth in spite of changing the assortment, pricing. Private brands are a stated growth driver for SS.

Valuation

SS is currently trading at P/E of 35.8x on FY26 basis. We value the stock based on P/E methodology and assign multiple of 30x on FY26E PAT of Rs 2,248mn to arrive at a target price of **Rs613** per share, which is a potential downside of 16.3% from current market price and recommend **"Sell"** on the stock.



East India Securities Ltd
 Excellent | Investment | Solutions

Rating: **Sell** Upside/(Downside): **-16%**
 CMP: **732** Target Price: **616**

Market Data

Bloomberg:	SHOP:IN
52-week H/L (Rs):	889 / 623
Mcap (Rs bn/USD bn):	80.4/1.0
Shares outstanding (mn):	110
Free float:	34.50%
Daily vol. (3mth Avg)	0.1mn
Face Value (Rs):	5

Source: ACE Equity, EISEC Research

Shareholding pattern

	Mar-24	Dec-23	Sep-23	Jun-23
Promoter	65.5	65.5	65.5	65.5
FII's	7.4	6.8	6.7	6.8
DII's	22.1	21.9	21.5	21.3
Public/others	5.8	05.8	6.3	6.3

Source: Ace Equity

Price Performance (%)*

YE Mar (R)	1M	3M	6M	12M
BSE 500	2.4	5.8	24.4	36.7
SS	-3.4	-0.9	17.4	8.3

*As on 21 January 2024 Source: BSE, EISEC Research

Shalini Gupta

Senior Research Analyst
 +91 22 6192 5344
 shalinig@eisec.com

Y/E Mar (Rs mn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	YoY (%)	Fully DEPS	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY22	26,275	-49.2%	3,780	14.4%	-724	96%	-6.6	NA	3.9%	-111.2	21.4
FY23	40,221	53.1%	6,953	17.3%	1,180	NA	10.7	83.7%	17.3%	68.2	11.5
FY24	43,166	7.3%	7,150	16.6%	828	-30%	7.5	32.7%	13.9%	97.2	11.2
FY25E	48,307	11.9%	8,176	16.9%	1,279	54%	11.6	39.8%	15.4%	62.9	9.8
FY26E	55,036	13.9%	9,576	17.4%	2,248	76%	10.7	54.9%	19.8%	35.8	8.3

Source: Company, EISEC Research Estimates

Conference Call Highlights

- **Wedding demand** during Q4FY24 was weaker than last year.
- **Delay in winter season** and early EOSS in December 2023 impacted overall Q4 performance.
- **Healthy recovery** in March 2024 as it grew 9% yoy on LTL (like to like) basis. Sales growth in January / February / March were flat / +6% / +13.5% over last year respectively.
- **Performance** was driven by Intune and brands (especially non-apparel). Apparel segment grew at low single-digit during Q4. First two weeks of April have been good.
- **INTUNE** : sales of Rs 160mn.
- **No of stores (Q4FY24 end)** : there were 112 DS (up 14% yoy), 7 Home Stop Stores (flat yoy), 87 Beauty Stores (down 39% yoy not including shop in shop stores), 21 Airport Stores (down 9.0% yoy). Thus, total Stores were 249 (down 8% yoy).
- **Square feet addition in space** : total space is 4.3mn sq ft (up 10% yoy).
- **Plans for expansion** : The management has a plan to add 60 INTUNE and 15 DS respectively in FY25.
- **Average selling price (ASP)** : ASP increased by 6% yoy.
- **Private brands** : Stop men's formal was up 22% yoy.
- **Private brands** : Advancement of EOSS (end of season sales) and soft sales in western wear/mens' category continued to impact performance.
- **Beauty** : New Store Launched i.e. Largest SSBeauty Store at Quest mall Kolkata.
- **Capex** : plan of Rs 2.50-2.75bn (funded by internal accruals) for FY25 with higher capital allocation towards department stores, INTUNE and beauty. It plans to open approx. 100 stores (incl. 60 INTUNE and 15 department stores) and renovate a few stores.

Quarterly financials, operating metrics and key performance indicators

Quarterly Financials

Y/E March (Rs mn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q3FY23
Net Sales	9,484	10,127	11,371	9,239	9,936	10,391	12,375	10,463	
Raw Materials	5,445	5,928	6,690	5,221	5,694	6,133	7,455	6,161	
Employee Costs	829	873	891	931	985	1,003	994	948	
Other Expenditure	1,586	1,674	1,662	1,541	1,539	1,666	1,752	1,688	
EBITDA	1,625	1,652	2,128	1,547	1,719	1,589	2,175	1,667	
Depreciation	846	927	999	1,045	1,050	1,062	1,113	1,120	
Interest	511	514	515	551	541	549	586	586	
Other Income	56	39	244	229	73	106	34	346	
PBT	324	250	858	181	200	84	510	306	
Tax	95	68	230	38	55	8	141	69	
Tax rate (%)	29%	27%	27%	21%	27%	9%	28%	22%	
PAT	228	182	628	143	145	76	369	238	
YoY Growth (%)									
Revenue	362.1%	57.7%	18.7%	28.0%	4.8%	2.6%	8.8%	13.3%	
EBITDA	NA	128.4%	15.7%	82.6%	5.8%	-3.8%	2.2%	7.7%	
Adj. PAT	NA	NA	24.6%	NA	-36.5%	-58.0%	-41.2%	66.3%	
QoQ Growth (%)									
Revenue	31.4%	6.8%	12.3%	-18.7%	7.5%	4.6%	19.1%	-15.4%	
EBITDA	91.8%	1.7%	28.8%	-27.3%	11.1%	-7.5%	36.9%	-23.4%	
Adj. PAT	NA	-20.3%	244.9%	-77.2%	1.5%	-47.3%	383.2%	-35.6%	
Margin (%)									
EBITDA	17.1%	16.3%	18.7%	16.7%	17.3%	15.3%	17.6%	15.9%	
PAT	2.4%	1.8%	5.5%	1.5%	1.5%	0.7%	3.0%	2.3%	

Source: Company, EISEC Research

Financials Consolidated

Income Statement	FY22	FY23	FY24	FY25E	FY26E
YE March (Rs mn)					
Revenues	26,275	40,221	43,166	48,307	55,036
% Growth	-49.2%	53.1%	7.3%	11.9%	13.9%
Operating Expenses	15,060	23,284	25,442	28,071	31,811
% of sales	57.3%	57.9%	58.9%	58.5%	57.8%
Personnel	2,725	3,523	3,930	4,630	5,228
% of sales	10.4%	8.8%	9.1%	9.6%	9.5%
Other expenses	4,709	6,462	6,644	7,430	8,421
% of sales	17.9%	16.1%	15.4%	15.4%	15.3%
EBITDA	3,780	6,953	7,150	8,176	9,576
EBITDA Margin (%)	14.4%	17.3%	16.6%	16.9%	17.4%
Other Income	590	567	558	598	1,651
Depreciation & Amortization	3,548	3,816	4,345	4,706	5,832
Extraordinary Items	0	-20	0	0	0
EBIT	822	3,683	3,363	4,068	5,395
Finance cost	2,066	2,092	2,263	2,316	2,316
PBT	-1,244	1,592	1,100	1,752	3,079
Tax-Total	-520	432	272	473	831
Reported PAT	-724	1,160	828	1,279	2,248
Minority Interest	0	0	0	0	0
Adjusted PAT	-724	1,180	828	1,279	2,248
PAT Margin	-2.8%	2.9%	1.9%	2.6%	4.1%
% Growth	96.4%	NA	-29.8%	54.4%	75.7%

Source: Company, EISEC Research Estimates

Key Ratios	FY22	FY23	FY24	FY25E	FY26E
YE March					
Growth Ratios (%)					
Net Sales	-49.2%	53.1%	7.3%	11.9%	13.9%
EBITDA	-122.2%	83.9%	2.8%	14.4%	17.1%
Adjusted Net Profit	96.4%	NA	-29.8%	54.4%	75.7%
Margin Ratio (%)					
EBITDA Margin	14.4%	17.3%	16.6%	16.9%	17.4%
PBT margins	-4.7%	4.0%	2.5%	3.6%	5.6%
PAT Margin	-2.8%	2.9%	1.9%	2.6%	4.1%
Return Ratios					
ROE	NA	83.7%	32.7%	39.8%	54.9%
ROCE	3.9%	17.3%	13.9%	15.4%	19.8%
ROIC	1.1%	14.9%	11.8%	13.3%	14.1%
Turnover Ratios (days)					
Gross Block Turnover (x)	1.3	1.8	1.6	1.8	2.0
Inventory	140.0	136.1	142.6	145.0	135.0
Debtors	4.4	2.7	7.0	6.0	6.0
Creditors	200.3	165.9	166.6	166.0	166.0
Cash Conversion Cycle	-56.0	-27.2	-17.0	-15.0	-25.0
Solvency ratio (x)					
Net Debt-Equity	0.7	-0.1	-0.1	-0.1	-0.2
Gross Debt/EBITDA	1.2	0.1	0.0	0.0	0.0
Current ratio	0.8	0.8	0.8	0.7	0.6
Per share (Rs.)					
Basic EPS (reported)	-6.6	10.7	7.5	11.6	20.4
BV	8.6	23.4	34.3	38.8	54.4
CEPS	25.7	45.3	47.0	54.4	73.5
DPS	0.0	0.0	0.0	8.0	8.0
Dividend Payout (%)	0.0	0.0	0.0	0.7	0.4
Valuation					
P/E	-111.2	68.2	97.2	62.9	35.8
P/BV	84.8	31.2	21.4	18.9	13.5
EV/EBITDA	21.4	11.5	11.2	9.8	8.3

Source: Company, EISEC Research Estimates

Balance Sheet	FY22	FY23	FY24	FY25E	FY26E
YE March (Rs mn)					
Capital	548	548	550	550	550
Reserves & Surplus	212	1,512	2,464	2,863	4,231
Shareholders' Funds	759	2,061	3,014	3,413	4,781
Minority Interest	0	0	0	0	0
Total Loan Funds	896	208	0	0	0
Lease liability	18,995	19,768	23,168	23,168	23,168
Total Liabilities	20,650	22,037	26,181	26,581	27,949
Gross Block	9,225	13,390	0	9,167	15,372
Accumulated Dep.	5,448	9,264	0	4,706	10,538
Net Block	3,777	4,126	5,044	4,461	4,834
Intangible assets	684	532	475	532	532
Capital WIP	140	296	174	180	200
Right of use assets	12,764	16,361	20,337	24,021	27,957
Total fixed assets	17,225	21,018	25,855	29,014	33,323
Investments	1,460	480	40	40	40
Other non current assets	5,502	5,514	5,144	6,811	7,760
Total Non Current Assets	7,102	6,290	5,358	7,031	8,000
Inventories	10,075	14,998	16,866	19,191	20,356
Short term loans & advances	130	0	41	0	0
Sundry Debtors	315	294	824	794	905
Cash & Bank Balances	328	314	167	381	830
Other current Assets	2,642	3,121	3,834	1,000	1,000
Total Current Assets	13,490	18,727	21,732	21,366	23,090
Sundry Creditors	14,418	18,285	19,703	21,970	25,030
Other current liabilities	1,409	1,903	2,380	5,559	6,333
Provisions	77	40	2	2	2
Total Current Liabilities	17,166	23,999	26,763	30,830	36,465
Net Current Assets	-3,676	-5,272	-5,031	-9,465	-13,374
Total Assets	20,651	22,036	26,182	26,581	27,949

Source: Company, EISEC Research Estimates

Cash Flow	FY22	FY23	FY24	FY25E	FY26E
YE March (Rs mn)					
Operating profit before WC changes	4,370	7,500	7,708	8,774	11,227
Changes in working capital	437	-927	-1,294	6,025	2,559
Cash flow from operations	5,328	6,141	6,143	14,326	12,955
Capex	159	-2,215	-1,378	-2,756	-2,770
Long term advances	1,615	0	41	-48	-7
Other non current assets	-2,037	-12	329	-1,619	-942
Others	-2,518	-2,129	-3,252	-6,361	-5,459
Cash flow from investments	-2,964	-3,377	-3,820	-10,785	-9,178
Cash flow from financing	-2,458	-2,778	-2,470	-3,328	-3,328
Net change in cash	-94	-14	-147	213	449

Source: Company, EISEC Research Estimates

Disclaimer

East India Securities Limited (hereinafter EISEC), a public company, registered as Research Analyst with SEBI (Registration No. INH300003231). EISEC is engaged in broking services, distribution and marketing of financial products, and in the normal course of business, EISEC prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

Research report is a written or electronic communication that includes research analysis, research recommendation or an opinion concerning securities or public offer, providing a basis for investment decisions. The views expressed therein are based solely on information available publicly/internal data/other reliable sources believed to be true. The information is provided merely as a complementary service and do not constitute an offer, solicitation for the purchase or sale of any financial instruments, inducement, promise, guarantee, warranty, or as an official confirmation of any transactions or contract of any kind.

Research data and reports published/ emailed/ text messaged via Short Messaging Services, Online Messengers, WhatsAppetc/transmitted through mobile application/s, including but not limited to FLIP™, Video Widget, telephony networks, print or electronic media and or those made available/uploaded on social networking sites (e.g. Facebook, Twitter, LinkedIn etc) by EISEC or those recommendation or offers or opinions concerning securities or public offer which are expressed as and during the course of "Public Appearance" are for informational purposes only. The reports are provided for assistance and are not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Though disseminated to clients simultaneously, not all clients may receive the reports at the same time. EISEC will not treat recipients as clients by virtue of their receiving this report.

The reports include projections, forecasts and other predictive statements which represent EISEC's assumptions and expectations in the light of currently available information. These projections and forecasts are based on industry trends, circumstances and factors which involve risks, variables and uncertainties. The actual performance of the companies represented in the report may vary from those projected. The projections and forecasts described in this report should be evaluated keeping in mind the fact that these-

- are based on estimates and assumptions
- are subject to significant uncertainties and contingencies
- will vary from actual results and such variations may increase over a period of time
- are not scientifically proven to guarantee certain intended results
- are not published as a warranty and do not carry any evidentiary value.
- are not based on certain generally accepted accounting principles
- are not to be relied on in contractual, legal or tax advice.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Reports based on technical analysis is focused on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Though we review the research reports for any untrue statements of material facts or any false or misleading information, , we do not represent that it is accurate or complete and it should not be relied on in connection with a commitment or contract whatsoever. Because of the possibility of human, technical or mechanical error by our sources of transmission of Reports/Data, we do not guarantee the accuracy, adequacy, completeness or availability of any information and are not to be held responsible for any errors or omissions or for the results obtained from the use of such information. EISEC and/or its Affiliates and its officers, directors and employees including the analysts/authors shall not be in any way responsible for any indirect, special or consequential damages that may arise to any person from any inadvertent error in the information contained in the reports nor do they take guarantee or assume liability for any omissions of the information contained therein. Information contained therein cannot be the basis for any claim, demand or cause of action. These data, reports and information do not constitute scientific publication and do not carry any evidentiary value whatsoever.

The reports are not for public distribution. Reproduction or dissemination, directly or indirectly, of research data and reports of EISEC in any form is prohibited except with the written permission of EISEC. Persons into whose possession the reports may come are required to observe these restrictions. Opinions expressed therein are our current opinion as of the date appearing on the report only. Data may be subject to update and correction without notice. While we endeavour to update on a reasonable basis the information discussed in the reports, there may be regulatory, compliance, or other reasons that prevent us from doing so.

The reports do not take into account the particular investment objectives, financial situations, risk profile or needs of individual clients. The user assumes the entire risk of any use made of this information. Each recipient of the reports should make such investigation as deemed necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in such reports (including the merits and risks involved).

Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Investors may lose his/her entire investment under certain market conditions. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of investments referred to in research reports and the income from them may fluctuate. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

The recommendations in the reports are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The reports are non-inclusive and do not consider all the information that the recipients may consider material to investments. The reports are issued by EISEC without any liability/undertaking/commitment on the part of itself or any of its entities.

Recipients of the research reports should assume that entities of EISEC may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of the reports. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of reports/data/material, may, from time to time have 'long' or 'short' positions in, act as principal in, and buy or sell the securities thereof of companies mentioned therein or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as market maker in the financial instruments of the company/ies discussed therein or act as advisor or lender/borrower to such company/ies or have other potential conflicts of interests with respect to any recommendation and related information and opinions.

We further undertake that-

- No disciplinary action has been taken against the research analyst or EISEC by any authority in connection with their respective business activity.
- EISEC, Research analysts, persons reporting to research analysts and their relatives may have financial interests and material conflict of interest in the subject company.
- EISEC, Research analysts, persons reporting to research analysts and their relatives may have actual/beneficial ownership of 1% or more in the subject company's securities, at the month immediately preceding the date of publication of this research report.

Past performance is not a guide for future performance, future returns are not guaranteed and investors may suffer losses which may exceed their original capital.

The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

Shoppers Stop



Source: ACE Equity, EISEC Research

Analyst holding in stock: **No**

Key to EISEC Investment Rankings

Buy: Upside by >15%, Accumulate: Upside by 5% to 15%, Hold: Downside/Upside by -5% to +5%,

Reduce: Downside by 5% to 15%, Sell: Downside by >15%

East India Securities Ltd. (<http://www.eisec.com/>)

Office: - 202, Garnet Palladium, Pandit Motilal Nehru Marg, Panch Bawadi, Behind Express Zone, Malad East, Mumbai – 400097

Disclosure of Interest Statement		
1	Business activities of East India Securities Ltd (EISEC)	East India Securities Ltd (hereinafter referred to as “EISEC”) is a registered member of NSE (All Segments), MCX-SX (Currency Derivatives Segment) and BSE (All segments), Depository Participant of NSDL & CDSL.
2	Details of Disciplinary History of EISEC	EISEC has not been debarred/ suspended by SEBI or any other regulatory authority from accessing or dealing in securities market on behalf of clients.
3	Registration status of EISEC:	EISEC is registered with SEBI as a Research Analyst (SEBI Registration No INH300003231)
		Rajratan
4	Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest	Yes
5	Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6	Whether the research analyst or his relatives has any other material conflict of interest	No
7	Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8	Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No
10	Whether the Research Analyst has been engaged in market making activity of the subject company.	No
11	Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months;	No
12	Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No
13	Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No

Member (NSE and BSE)

Single SEBI Regn No.: INZ000190836

Research Analyst

SEBI Registration No. INH300003231

Website: www.eisec.com

Investor Grievance Email ID: mail@eisec.com

Compliance Officer Details:

Sumeet Kejriwal 033-40205901; Email ID: sumeetk@eisec.com

East India Securities Ltd. (CIN: U67120WB1995PLC072026)	
Registered Office Address DA-14 Saltlake City, Sector-1, Kolkata – 700064.	Corporate Office & Correspondence Address 202, Garnet Palladium, Pandit Motilal Nehru Marg, Panch Bawadi, Behind Express Zone, Malad East, Mumbai – 400097